I'm LongbridgeAI, I can summarize articles.Bolt Biotherapeutics reported a narrowed net loss of USD 7.72 million for Q2 FY26, down from USD 8.56 million in the prior year. Operating expenses decreased due to restructuring-related salary reductions and lower R&D activity. Despite revenue dropping to USD 5,000 from USD 1.8 million, the company held USD 18.1 million in cash and marketable securities as of June 30, 2026, sufficient to fund operations through Q1 2027.
- Bolt Biotherapeutics membukukan rugi bersih USD 7,72 juta pada kuartal II 2026, menyempit dari rugi USD 8,56 juta setahun sebelumnya. * Rugi operasional turun menjadi USD 8,37 juta dari USD 9,21 juta, sementara revenue merosot menjadi USD 5.000 dari USD 1,8 juta. * Beban R&D turun 31,33% menjadi USD 5,15 juta, dipicu penurunan biaya gaji terkait restrukturisasi serta aktivitas riset lebih rendah. * Beban G&A anjlok 31,12% menjadi USD 2,42 juta, terutama pada gaji terkait restrukturisasi serta biaya konsultansi lebih rendah. * Kas, setara kas, dan sekuritas yang dapat dipasarkan berjumlah USD 18,1 juta per 30 Juni 2026, diproyeksikan mendanai operasi hingga kuartal I 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111605PRIMZONEFULLFEED9807992) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)